Lexicon Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LEXICON PHARMS INC
LEXICON PHARMS INC has one approved drug.
There are three US patents protecting LEXICON PHARMS INC drugs.
There are seventy-one patent family members on LEXICON PHARMS INC drugs in thirty-three countries and twelve supplementary protection certificates in eleven countries.
Summary for Lexicon Pharms Inc
| International Patents: | 71 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Lexicon Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 7,781,577 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 8,476,413 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 8,217,156 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Lexicon Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2013079243 | ⤷ Start Trial |
| Hong Kong | 1183020 | ⤷ Start Trial |
| Mexico | 2009003305 | ⤷ Start Trial |
| Denmark | 2332947 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lexicon Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2089361 | CA 2019 00042 | Denmark | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | 42/2019 | Austria | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1363 (MITTEILUNG) 20190430 |
| 2089361 | 2019C/538 | Belgium | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZINE OF EEN AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1363 20190430 |
| 2089361 | 1990043-0 | Sweden | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1363 20190430 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
